Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

The CSF3R T618I Mutation Found In Chronic Neutrophilic Leukemia Removes An O-Linked Glycosylation Site and Increases Receptor Dimerization

Blood (2013) 122 (21): 270.

https://doi.org/10.1182/blood.V122.21.270.270

Published: 2013

Journal Articles

Pillar-1: Multicenter Phase 2 Study of Everolimus for Patients with Mantle Cell Lymphoma Who Are Refractory or Intolerant to Bortezomib.

Michael Wang, M.D., Leslie Popplewell, MD, Robert H. Collins, Jr., MD, Jane N. Winter, MD, Andre Goy, MD, Anna Robeva, MS, Nicoletta Pirotta, Jenna Fan, Judith Klimovsky, MD, Owen A. O'Connor, MD, PhD

Blood (2012) 120 (21): 2751.

https://doi.org/10.1182/blood.V120.21.2751.2751

Published: 2012

Journal Articles

Single Agent Bendamustine Is An Effective Pre-Vaccine Treatment for Patients with Relapsed Follicular Lymphoma Undergoing Idiotypic Vaccination

Maurizio Bendandi, MD, PhD, Carlos Becerra, MD, Joseph Kuhn, MD, Suncica Hukic, Nyla Langford, Taizoon Khokhar, Victor Klimyuk, PhD, Yuri Gleba, PhD, Romy Kandzia, PhD, Frank Thieme, PhD, Franziska Jarczowski, Jens Uwe Kuenstler, PhD, Madhuri Vusirikala, MD, Nora Ku, MD, Robert H. Collins, Jr., MD

Blood (2011) 118 (21): 2691.

https://doi.org/10.1182/blood.V118.21.2691.2691

Published: 2011

Journal Articles

Idiotypic Vaccination of Patients with Relapsed Follicular Lymphoma Using a Novel Vaccine Formulation Including a Tobacco Plant-Produced Tumor Specific Idiotype

Blood (2011) 118 (21): 1649.

https://doi.org/10.1182/blood.V118.21.1649.1649

Published: 2011

Journal Articles

Prolonged Administration of the Telomerase Vaccine GRNVAC1 Is Well Tolerated and Appears to Be Associated with Favorable Outcomes In High-Risk Acute Myeloid Leukemia (AML)

H. Jean Khoury, MD, FACP, Robert H. Collins, Jr, MD, William Blum, MD, Lori Maness, MD, Patrick Stiff, MD, Stephen M. Kelsey, MD, Anita Reddy, PhD, Jennifer A. Smith, PhD, John F. DiPersio, MD, PhD

Blood (2010) 116 (21): 2190.

https://doi.org/10.1182/blood.V116.21.2190.2190

Published: 2010

Journal Articles

Immune Responses in AML Patients Following Vaccination with GRNVAC1, Autologous RNA Transfected Dendritic Cells Expressing Telomerase Catalytic Subunit hTERT.

John F. DiPersio, MD, PhD, Robert H. Collins, Jr., MD, William Blum, MD, Marcel P Devetten, M.D., Patrick Stiff, MD, Laurence Elias, MD, Anita Reddy, Ph.D., Jennifer A. Smith, Ph.D., H. Jean Khoury, MD

Blood (2009) 114 (22): 633.

https://doi.org/10.1182/blood.V114.22.633.633

Published: 2009

NARROW

The CSF3R T618I Mutation Found In Chronic Neutrophilic Leukemia Removes An O-Linked Glycosylation Site and Increases Receptor Dimerization

Pillar-1: Multicenter Phase 2 Study of Everolimus for Patients with Mantle Cell Lymphoma Who Are Refractory or Intolerant to Bortezomib.

Single Agent Bendamustine Is An Effective Pre-Vaccine Treatment for Patients with Relapsed Follicular Lymphoma Undergoing Idiotypic Vaccination

Idiotypic Vaccination of Patients with Relapsed Follicular Lymphoma Using a Novel Vaccine Formulation Including a Tobacco Plant-Produced Tumor Specific Idiotype

Prolonged Administration of the Telomerase Vaccine GRNVAC1 Is Well Tolerated and Appears to Be Associated with Favorable Outcomes In High-Risk Acute Myeloid Leukemia (AML)

Immune Responses in AML Patients Following Vaccination with GRNVAC1, Autologous RNA Transfected Dendritic Cells Expressing Telomerase Catalytic Subunit hTERT.

Email alerts

ASH Publications

American Society of Hematology

The CSF3R T618I Mutation Found In Chronic Neutrophilic Leukemia Removes An O-Linked Glycosylation Site and Increases Receptor Dimerization

Pillar-1: Multicenter Phase 2 Study of Everolimus for Patients with Mantle Cell Lymphoma Who Are Refractory or Intolerant to Bortezomib.

Single Agent Bendamustine Is An Effective Pre-Vaccine Treatment for Patients with Relapsed Follicular Lymphoma Undergoing Idiotypic Vaccination

Idiotypic Vaccination of Patients with Relapsed Follicular Lymphoma Using a Novel Vaccine Formulation Including a Tobacco Plant-Produced Tumor Specific Idiotype

Prolonged Administration of the Telomerase Vaccine GRNVAC1 Is Well Tolerated and Appears to Be Associated with Favorable Outcomes In High-Risk Acute Myeloid Leukemia (AML)

Immune Responses in AML Patients Following Vaccination with GRNVAC1, Autologous RNA Transfected Dendritic Cells Expressing Telomerase Catalytic Subunit hTERT.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only